| Section/Item         | Item No | Recommendation                                                                                      | Reported on Page Number/Line Number | Reported on Section/Paragraph |
|----------------------|---------|-----------------------------------------------------------------------------------------------------|-------------------------------------|------------------------------|
| Title and abstract   | 1       | (a) Indicate the study’s design with a commonly used term in the title or the abstract                | Page 2/Line 42-53                   | Abstract/Para 1-2             |
|                      |         | (b) Provide in the abstract an informative and balanced summary of what was done and what was found   | Page 2-3/Line 54-70                 | Abstract/Para 3-4             |
| Introduction         |         |                                                                                                     |                                     |                              |
| Background/ rationale| 2       | Explain the scientific background and rationale for the investigation being reported                 | Page 3/Line 76-84                   | Introduction/Para 1           |
| Objectives           | 3       | State specific objectives, including any prespecified hypotheses                                      | Page 3/Line 85-95                   | Introduction/Para 2           |
| Methods              |         |                                                                                                     |                                     |                              |
| Study design         | 4       | Present key elements of study design early in the paper                                              | Page 4/Line 101-106                 | Methods/Para 1               |
| Setting              | 5       | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | Page 3-4/Line 98-103                | Methods/Para 1               |
| Participants         | 6       | (a) **Cohort study**—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up | Page 4/Line 108-115                 | Methods/Para 3               |
|                      |         | **Case-control study**—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls |                                     |                              |
|                      |         | **Cross-sectional study**—Give the eligibility criteria, and the sources and methods of selection of participants |                                     |                              |
|                      |         | (b) **Cohort study**—For matched studies, give matching criteria and number of exposed and unexposed **Case-control study**—For matched studies, give matching criteria and the number of controls per case | Page 4-5/Line 125-129               | Methods/Para 4               |
| Variables            | 7       | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | Page 5/Line 147-152                 | Methods/Para 7               |
| Data sources/measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | Page 4/Line 117-123                 | Methods/Para 3               |
| Bias                 | 9       | Describe any efforts to address potential sources of bias                                             | Page 4-5/Line 125-129               | Methods/Para 4               |
| Study size           | 10      | Explain how the study size was arrived at                                                              | Page 4/Line 101-103                 | Methods/Para 1               |
| Quantitative variables | 11  | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | Page 5/Line 147-152                 | Methods/Para 7               |
| Section | Paragraph | Page/Line | Methods/Para |
|---------|-----------|-----------|--------------|
| **Methods** | 12 | (a) Describe all statistical methods, including those used to control for confounding | Page 5/Line 147-152 | 7 |
| | | (b) Describe any methods used to examine subgroups and interactions | Page 5/Line 147-152 | 7 |
| | | (c) Explain how missing data were addressed | Page 5/Line 147-152 | 7 |
| | | (d) **Cohort study**—If applicable, explain how loss to follow-up was addressed | Page 5/Line 147-152 | 7 |
| | | **Case-control study**—If applicable, explain how matching of cases and controls was addressed | Page 5/Line 147-152 | 7 |
| | | **Cross-sectional study**—If applicable, describe analytical methods taking account of sampling strategy | Page 5/Line 147-152 | 7 |
| | | (e) Describe any sensitivity analyses | Page 5/Line 147-152 | 7 |
| **Results** | | | |
| **Participants** | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | Page 5-6/Line 155-161 | 1 |
| | | (b) Give reasons for non-participation at each stage | Page 5-6/Line 155-161 | 1 |
| | | (c) Consider use of a flow diagram | Page 5-6/Line 155-161 | 1 |
| **Descriptive data** | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | Page 6-7/Line 162-214 | 1-2 |
| | | (b) Indicate number of participants with missing data for each variable of interest | Page 6-7/Line 162-214 | 1-2 |
| | | (c) **Cohort study**—Summarise follow-up time (eg, average and total amount) | Page 6-7/Line 162-214 | 1-2 |
| **Outcome data** | 15* | **Cohort study**—Report numbers of outcome events or summary measures over time | Page 8/Line 216-228 | 3 |
| | | **Case-control study**—Report numbers in each exposure category, or summary measures of exposure | Page 8/Line 216-228 | 3 |
| | | **Cross-sectional study**—Report numbers of outcome events or summary measures | Page 8/Line 216-228 | 3 |
| **Main results** | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | Page 8/Line 216-228 | 3 |
| | | (b) Report category boundaries when continuous variables were categorized | Page 8/Line 216-228 | 3 |
| | | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | Page 8/Line 216-228 | 3 |
| **Other analyses** | | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | Page 8/Line 230-237 | 4 |
| **Discussion** | | | |
| **Key results** | 18 | Summarise key results with reference to study objectives | Page 9/Line 265-271 | 3 |
| **Limitations** | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | Page 10/Line 272-281 | 4 |
| Interpretation   | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | Page 10/Line 282-287 | Discussion/Para 4 |
|------------------|----|-------------------------------------------------------------------------------------------------|----------------------|------------------|
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | Page 10/Line 282-287 | Discussion/Para 4 |

**Other information**

| Funding   | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | Page 11/Line 318-322 | Acknowledgments |

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.